NUVBPDUFA
IBTROZI (Taletrectinib) (ROS1 inhibitor)
TKI-naïve and TKI-pretreated advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC)
Approval decisionFDA regulatory calendar
Track FDA action dates and advisory committee meetings by month. Each event links to its company, drug, indication and source-backed research record.
FDA regulatory calendar
TKI-naïve and TKI-pretreated advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC)
Approval decisionUse the monthly FDA calendar to review PDUFA target dates and advisory committee meetings, then open each event for drug, company, indication and source context.